Molecular targets of developmental exposure to bisphenol A in diabesity: a focus on endoderm-derived organs

I. Porreca,[1,†] L. Ulloa-Severino,[1,2†] P. Almeida,[3] D. Cuomo,[1] A. Nardone,[5] G. Falco,[1,6] M. Mallardo[7] and C. Ambrosino[1,4]

[1]IRGS, Biogem, Ariano Irpino, Italy, [2]PhD School in Nanotechnology, University of Trieste, Trieste, Italy, [3]STAB VIDA-Investigação e Serviços em Ciências Biológicas, Madan Parque, Caparica, Portugal, [4]Department of Science and Technology, University of Sannio, Benevento, Italy, [5]Department of Public Health, University of Naples 'Federico II', Naples, Italy, [6]Department of Biology, University of Naples 'Federico II', Naples, Italy, and [7]Molecular Medicine and Medical Biotechnologies, University of Naples 'Federico II', Naples, Italy

Address for correspondence: I Porreca, IRGS, Biogem, Via Camporeale, 83031 Ariano Irpino, Avellino, Italy.

E-mail: immacolata.porreca@biogem.it

C Ambrosino, Department of Science and Technology, University of Sannio, via Port'Arsa 11, 82100 Benevento, Italy.

E-mail: coambros@unisannio.it

[†]Both authors contributed equally to this work.

Summary

Several studies associate foetal human exposure to bisphenol A (BPA) to metabolic/endocrine diseases, mainly diabesity. They describe the role of BPA in the disruption of pancreatic beta cell, adipocyte and hepatocyte functions. Indeed, the complexity of the diabesity phenotype is due to the involvement of different endoderm-derived organs, all targets of BPA.

Here, we analyse this point delineating a picture of different mechanisms of BPA toxicity in endoderm-derived organs leading to diabesity. Moving from epidemiological data, we summarize the *in vivo* experimental data of the BPA effects on endoderm-derived organs (thyroid, pancreas, liver, gut, prostate and lung) after prenatal exposure. Mainly, we gather molecular data evidencing harmful effects at low-dose exposure, pointing to the risk to human health. Although the fragmentation of molecular data does not allow a clear conclusion to be drawn, the present work indicates that the developmental exposure to BPA represents a risk for endoderm-derived organs development as it deregulates the gene expression from the earliest developmental stages.

A more systematic analysis of BPA impact on the transcriptomes of endoderm-derived organs is still missing. Here, we suggest *in vitro* toxicogenomics approaches as a tool for the identification of common mechanisms of BPA toxicity leading to the diabesity in organs having the same developmental origin.

Keywords: Bisphenol A, endoderm-derived organs, epigenetics, perinatal exposure.

Abbreviations: BPA, bisphenol A; ER, oestrogen receptor; GD, gestation day; GPR30, G protein coupled receptor 30; 0mER, membrane-associated ER; NF-kB, nuclear factor kappa B; NHANES, National Health and Nutrition Examination Survey; PND, postnatal day; T2D, type 2 diabetes; T_4, tetra-iodothyronine; TH, thyroid hormone; XME, xenobiotic-metabolizing enzyme.

Introduction

Human exposure to bisphenol A (BPA), used in the manufacturing of several products as polycarbonate plastics, is continuous and widespread. Ingestion is thought to be the primary source of human exposure (1–4). Several studies showed its rapid transformation into an inactive form (5). The residual active form is in small amounts, not

1

raising concern if we exclude that metabolites can also exert toxic activity. BPA acts with a nonmonotonic dose–response curve (6,7), typical of natural hormones and other endocrine-disrupting compounds, complicating the extrapolation of a threshold daily exposure dose from experimentally determined high-dose effects (8).

Human exposure to BPA has been associated with different diseases including the diabesity (obesity associated to type 2 diabetes [T2D]) (9). Indeed, BPA differentially interferes with several hormonal signalling pathways. The ability of BPA to interfere with oestrogen signalling was accepted from the early beginning. It was considered a weak oestrogen because its binding affinity to the oestrogen receptors (ERs) alpha and beta was estimated to be over 1,000–10,000-fold lower than the natural hormone E2 (10,11). However, more recent studies have demonstrated that BPA oestrogenicity can be exerted through ER-dependent extra-nuclear mechanisms, at similar or stronger levels than E2 (12,13). It acts by binding to membrane-associated ER (mER) and the G protein coupled receptor 30 (GPR30), for which it shows higher binding affinities than for ERs (14–16). In addition, at low dose, BPA affects the pathways related to the thyroid receptor (17) and to the nuclear oestrogen-related receptor γ (18). At higher concentrations, BPA can also act on the androgen receptor (19). Other mechanisms of low-dose BPA toxicity include the pathways related to oxidative stress (20), such as the Nuclear Factor kappa B (NF-kB) (21,22) and, finally, epigenetic modifications (23). The last is an important issue because the adverse effects of a foetal/neonatal exposure can remain undetected till diseases develop in adulthood.

The BPA has been detected in amniotic fluid, neonatal blood, placenta, cord blood and human breast milk (2). Infants and foetuses are more susceptible \to its effects because of their rapid development and reduced detoxification ability during pregnancy observed in both rodents (24) and humans (25). Indeed, BPA shows limited binding to alpha fetoprotein, a protein that binds oestrogens and protects the developing tissues from excessive exposure, resulting in an increased access for BPA to oestrogen-sensitive tissues (26,27). Altogether BPA can exert greater effects on development than expected.

The BPA toxicity data are often contrasting, and they have been already reviewed specifically for some endoderm-derived organs (28–33). These organs develop from a specific position of the primitive gut in response to inductive signals from surrounding tissues, activating specific transcriptional programmes. Although not confirmed in the Good Laboratory Practice (GLP) studies (34,35), academic research provided evidence that BPA can alter the function of endoderm-derived organs like liver, thyroid and pancreas as well as, recently, prostate, gut and lung (36–47).

Considering the recent advances in the understanding of stem cell biology and transdifferentiation processes, here, we analyse the published research to explore the effects of developmental exposure to BPA, via maternal intake, exerted on the endoderm-derived organs and playing a direct or indirect role in the diabesity phenotype in the adulthood. The effects of BPA exposure on the metabolic–endocrine functions of some of these organs have been partially summarized at epigenetic/molecular level (9). As molecular data are limited, we analysed in detail an *in vitro* toxicogenomic analysis, conducted in our laboratory on thyrocytes, that suggests mechanisms of BPA toxicity also in other endoderm-derived tissues involved in diabesity.

Impact of developmental exposure to bisphenol A on endoderm-derived organs

The metabolic imbalance and diabesity associated to early exposure to BPA are the object of different reports, often focused on two endoderm-derived organs: liver and pancreas (9). Recently published works underline the involvement of other endoderm-derived organs in diabesity, although it is debated if their impairment is a cause or an outcome of the pathological condition. Here, we analyse those works describing the damages of endoderm organs upon *in utero* exposure to BPA in animal models, referring to the diabesity phenotype. We will discuss molecular data to highlight 'phenotype anchoring' aspects.

Liver

The liver plays a relevant part in the metabolic balance impaired in the diabesity phenotype (48). Indeed, the increased expression of hepatic genes involved in glycolysis and lipogenesis is pivotal in the enhancement of insulin resistance (49).

Human foetal exposure has been confirmed by the detection of BPA in foetal liver samples, at concentrations ranging between 1.3 and $27 \, ng \, g^{-1}$ (50,51). The BPA molecular targets in foetal liver have been investigated in animal models. It altered the expression of key markers of hepatocyte maturation (i.e. glycogen synthase), of immature hepatocytes (alpha fetoprotein) and of CCAAT/enhancer binding protein alpha (C/EBP-α), a hepatocyte-specific transcription factor, impairing the maturation of mouse livers in female foetuses exposed via maternal diet (E7.5–E18.5). Increased expression of the xenobiotic-metabolizing enzyme (XME), Cyp1a1 and Gst, was described only in livers of murine embryos exposed to $200 \, \mu g \, kg^{-1} \, d^{-1}$ of BPA, although other doses were tested (52). In contrast, the inhibition of XME transcripts and the hypermethylation of their promoters were reported in foetal human livers specimen (BPA range: $35.4–56.1 \, ng \, g^{-1}$) (53). The described results were not really contrasting (52) as different genes/proteins of the XMEs family were monitored and the liver or plasma level of BPA was not determined in the mouse study. In addition, the perinatal exposure to BPA determined liver

damages in adult rats exposed to $50\,\mu g\,kg^{-1}\,d^{-1}$ of BPA (reference dose) from conception to weaning. Increased apoptosis of adult hepatic cells, because of altered expression of Bcl-2 family genes, was observed (54). In similar experimental settings, a decrease in the global hepatic DNA methylation and the specific hypermethylation of the hepatic *glucokinase* promoter were described in 3- and 21-week old rats. The resulting inhibition of *glucokinase* transcript could contribute to insulin resistance (55).

The modifications of hepatic methylome were investigated by genome-wide analysis of liver DNA, conducted at postnatal day (PND) 22, in mice exposed to multiple doses of BPA through the maternal diet (56). Interestingly, they involved well-known targets of BPA, such as Myh7b and Slc22a12. These results were not confirmed in another work, similarly conducted, in which less sensitive techniques were used (global DNA methylation – High-performance liquid chromatography) (57). Sex-specific epigenetic mechanisms have been recently described for the inhibition of *Cpt1a* and other fatty acid β-oxidation transcripts in liver of male rats exposed to $100\,\mu g\,kg^{-1}\,d^{-1}$ of BPA from gestation day (GD) 6 to PND21, developing the steatosis in adulthood (58).

The XME enzymes are considered factors of progression in diabesity (59) and in the imbalance of the energetic metabolism (60); therefore, they are the molecular targets of BPA in diabesity. In addition, the analysis of mice metabolome suggested that BPA could affect the energetic metabolism impairing the mitochondrial pathways (61). The results were confirmed at molecular level in a study characterizing the fatty liver disease developed during adulthood in rats exposed to $40\,\mu g\,kg^{-1}\,d^{-1}$ of BPA from GD0 to PND21. The upregulation of genes involved in lipogenesis pathways, Reactive Oxygen Species generation and cytochrome C release from mitochondria in liver was detected already at 3 weeks, when liver morphology and function were still normal (62).

In summary, prenatal and perinatal exposure to BPA can damage liver activity deregulating gene expression by sex-specific epigenetic mechanisms, implied in the diabetes (63). The summarized molecular modifications are involved in the diabesity phenotype progression, in particular, the ones related to mitochondrial dysfunctions and resulting in damage of redox homeostasis (64).

Pancreas

Exposure to BPA has been epidemiologically associated with T2D, insulin resistance and obesity (65,66). BPA administration ($10\,\mu g\,kg^{-1}\,d^{-1}$, GD9–GD16) could predispose adult male offspring to T2D development (36). The pancreatic beta cells, isolated from exposed animals, exhibited enhanced insulin secretion in response to basal level of glucose, altered calcium signalling and reduced proliferation rate (36). The results are in agreement with other *in vitro* and *in vivo* studies demonstrating that

BPA could damage pancreatic beta cells or other pancreatic cell types (37), whose impairment is strictly connected to T2D (67). The impairment of glucose homeostasis dependent on BPA has been documented in several other studies (68–70). The development of hyperglycaemia, hyperinsulinemia and glucose intolerance in adulthood was described in rats exposed to $50\,\mu g\,kg^{-1}\,d^{-1}$ of BPA from conception to weaning (71). Morphological (swollen mitochondria, dilated rough reticulum, etc.) and molecular changes (inhibition of specific transcripts such as *Pdx-1* and *Nkx6.1*) were described in beta cells isolated from exposed animals. Recently, the role of BPA exposure in proliferation and differentiation of beta cells has been confirmed in a report showing an altered α : β-cell ratio in islets prepared from the foetal pancreas of exposed animals (72). The critical window of susceptibility to BPA exposure on the development of dysglycaemia was characterized by exposing pregnant mice to $100\,\mu g\,kg^{-1}\,d^{-1}$ of BPA at different times during foetal/neonatal life and analysing the offspring at 3, 6 and 8 months of age. The study confirmed that male mice were more prone to developing T2D and identified the preimplantation period as the less vulnerable. All the morphological and functional damages of beta cells were confirmed, and a reduced rate of beta cells turnover within the islet was observed (73). BPA exposure accelerated spontaneous diabetes development in non-obese diabetic mice developmentally exposed from conception to weaning, through the dams' drinking water (0.1, 1 and $10\,mg\,L^{-1}$). Increased apoptosis of beta and glucagon-secreting cells was described, caused by damages of the immune system (37). Recently, Angle *et al.* have demonstrated the existence of a nonmonotonic relationship between BPA foetal exposure (from GD9 to GD18) and insulin sensitivity using a full range (from 5 to $50,000\,\mu g\,kg^{-1}\,d^{-1}$) of BPA doses. Insulin sensitivity decreased at the other tested doses, 500 and $50,000\,mg\,kg^{-1}\,d^{-1}$ of BPA (69).

Molecular pathways have been investigated in beta cells isolated from humans, mice and rats (12,14,74–77). BPA increased the insulin content and its release in the mouse pancreatic islets. The insulin gene expression was induced, in an inverted U-shape dose–response manner (14), by mechanisms involving nuclear ERs, mER and GPR30 (12,74). Other *in vitro* studies confirmed the role of mitochondria alteration (mass, morphology, etc.) and of *Bax* (induced) and *Bcl2* (reduced) gene expression in beta cells failure upon exposure (75). Similar results were shown in *ex vivo* mouse and rat pancreatic islets (76,77).

In summary, BPA is directly involved in islets failure, which is considered a critical aspect of diabesity in youth (78). Although the molecular mechanisms of BPA activity in beta cells have been described, they need further verification *in vivo*.

Thyroid

Thyroid hormones (THs) regulate glucose and lipid metabolism; therefore, diabesity and thyroid diseases appear to be closely linked (9,79,80). TH disruptors, such as BPA, can perturb the TH action in all body tissues through different mechanisms, in particular, antagonizing the activity of the thyroid receptor (17,44,81). Epidemiological data from the National Health and Nutrition Examination Survey (NHANES) study suggested an inverse relationship between BPA exposure and total tetra-iodothyronine (T_4) concentrations (82). Some aspects related to diabesity were also found to be impaired in the NHANES cohort (83,84). The thyroid effects were strengthened by another epidemiological study following women and their children (Center for the Health Assessment of Mothers and Children of Salinas cohort). High maternal urinary concentrations of BPA were significantly associated with lower maternal serum T_4 and negatively associated with neonatal thyroid-stimulating hormone in boys but not in girls (85).

Contradictory results have been reported in animal models. No alteration in serum T_4 levels, dosed at 1, 3 and 9 weeks of age, was retrieved in rat offspring of pregnant dams orally exposed to BPA (4–$400\,mg\,kg^{-1}\,d^{-1}$, GD6–PND20) (81). In contrast, BPA exposure (1–$50\,mg\,kg^{-1}\,d^{-1}$) from GD6 resulted in an increase of T_4 serum level only at PND15 in rat offspring. The increase resulted in an augmented expression of *RC3/neurogranin*, a TH target gene (38). A study executed at lower BPA doses (1 and $0.1\,mg\,kg^{-1}\,d^{-1}$), administered from GD11 to PND 21, reported a transient hyperthyroidism at PND7 followed by hypothyroidism at PND21 in male offspring (87).

In a model of a long-gestation species, with regulation and ontogenesis of thyroid function similar to humans (Lacaune sheep), the exposure to BPA ($5\,mg\,kg^{-1}\,d^{-1}$, GD28 end of pregnancy) decreased the total T_4 blood level in pregnant sheep and in newborns (30% decrease), disappearing at 2 months of age (88).

The BPA might alter thyroid homeostasis antagonizing TH signalling pathways (17,89). However, it is not possible to exclude a direct action of BPA on thyrocytes. This point was assessed *in vivo* (zebrafish embryos) and *in vitro* (immortalized rat thyrocytes) analysing the transcription of thyroid specific genes such as *thyroglobulin* (codifying for the precursor of TH) and *Pax8*, its main transcriptional regulator, in both experimental models exposed to low-dose BPA (21). This was the first evidence of a direct effect of BPA on thyroid cells, suggesting the involvement of the NF-*k*B and the Retinoic Acid Receptor/Retinoid X Receptor pathways in this activity. Other mechanisms of thyroid BPA toxicity as well as the deregulation of several pathways involved in the diabesity phenotype were evidenced in an *in vitro* transcriptomic analyses conduced on thyrocytes (90), among them insulin receptor signalling (p-value = 0.025)

and 1D-myo-inositol hexakisphosphate biosynthesis II and superpathway of inositol phosphate compounds (p-value = 0,035) (unpublished results) (91). The transcriptomic study suggested that the gene expression profiling of immortalized thyrocytes exposed to 1 nM of BPA could evidence the impairment of pathways and mechanisms of toxicity in other endoderm-derived organs, in which they have not been directly assessed.

Gut

The digestive tract is the largest endocrine-related organ system in the body, secreting several metabolic hormones (i.e. gherlin and leptin). Among the endoderm-derived organs, it is the only one characterized by a continuous and rapid renewal of its epithelial cells. Gastrointestinal morphology and function are affected in diabesity, in particular, with intestinal barrier impairment (92,93). Recent evidence describes 'leaky gut' as a factor involved in the development of diabesity. The destruction of the intestinal barrier and its permeability may enhance the natural interactions between intestinal bacterial products and hepatic receptors (e.g. toll-like receptors) promoting oxidative stress, insulin resistance and so on. The alterations of the junction systems in the intestinal epithelial cells are involved in the process (94).

Clinical and experimental evidence points to oestrogen and xenoestrogen (BPA among them) role in the development and regulation of the intestinal barrier (95). The impact of BPA on the intestinal function remains poorly explored although the gut is in direct contact with BPA when orally absorbed. BPA affects the gut permeability reducing Ca^{++} adsorption in pregnant mice (39,40). Perinatal exposure (GD15–PND21) to BPA ($5\,mg\,kg^{-1}\,d^{-1}$) impaired intestinal permeability and, consequently, increased the inflammatory response after colitis induction in female rats during adulthood. The increased transcription of tight junction proteins, occludin and junctional adhesion molecule A, was described in the mother's colon whereas ER beta transcript was found to be increased in the mothers and reduced in male offspring (39). In the same study, the reduction of intestinal permeability in the colon of neonates and adult female offspring was documented (39). Thus, the intestinal barrier is a target of BPA, and related damages, such as impairment of cell–cell junctions, can contribute to progression of inflammatory diseases and diabesity (94).

More detailed molecular mechanisms on modulation of junctions in intestinal mucosa are not available although it was characterized in the blood–testis barrier (96). We tried to gain further insights on this aspect by looking for cell junction-related information in the previously described *in vitro* toxicogenomics study (90). We evidenced the BPA effects on the cellular junction systems in immortalized thyrocytes (Table 1). Similar to gut epithelial cells, these cells are polarized and strictly connected. In thyrocytes,

Table 1 Tight junction-related genes deregulated in immortalized thyrocytes exposed to 1 nM of BPA as determined by microarray

Gene symbol	Fold change (BPA-treated vs. untreated cells)	Corrected *p*-value	Gene description
Utrn	−2.01	2.66E-05	Utrophin ([113])
Ctnna1	−2.07	1.41E-03	Catenin (cadherin-associated protein), alpha 1
Vcl	−2.09	2.81E-03	Vinculin ([114])
Camk2d[†]	−2.11	8.02E-04	Calcium/calmodulin-dependent protein kinase II delta
Nf2	−2.12	1.69E-04	Neurofibromin 2 (merlin) ([115])
Shroom3	−2.13	3.68E-04	Shroom family member 3 ([116])
Lrp4[†]	−2.13	5.00E-03	Low-density lipoprotein receptor-related protein 4
Csk	−2.15	1.90E-04	c-src tyrosine kinase ([117])
Snta1[†]	−2.24	3.80E-04	Syntrophin, acidic 1
Dlg1	−2.25	1.45E-04	Discs, large homolog 1 (Drosophila) ([118])
Akap1[†]	−2.26	1.50E-04	A kinase anchor protein 1
Tjp3	−2.26	1.43E-04	Tight junction protein 3 ([119])
Ptprm	−2.27	1.45E-04	Protein tyrosine phosphatase, receptor type ([120])
Itga5	−2.31	5.11E-04	Integrin, alpha 5 (fibronectin receptor, alpha polypeptide)
Pard3	−2.39	3.00E-05	Par-3 (partitioning defective) ([121])
Amotl2	−2.45	7.46E-04	Angiomotin like 2 ([122])
Numb	−2.48	1.58E-04	Numb homolog (Drosophila) ([123])
Dsg2	−2.52	6.28E-05	Desmoglein 2
Tjp2	−2.53	1.61E-04	Tight junction protein 2
Arhgef2	−2.63	1.97E-06	Rho/rac guanine nucleotide exchange factor 2 ([124])

Genes deregulated in immortalized thyrocytes after 7 d of exposure to 1 nM of BPA and selected for their involvement in cell junctions formation (the whole gene list is available at www.ebi.ac.uk/arrayexpress under the accession number E-MTAB-4458) (90).
[†]Gene involved in cytoskeleton organization and characterized only in the neuromuscular junction.
BPA, bisphenol A.

genes involved in tight junction (i.e. Tjp3 and Tjp2), adherens junctions (i.e. Vcl and Ctnn1a) and signal transduction and related cytoskeleton remodelling (i.e. Nf2) were inhibited. Although describing the BPA effects on junction transcripts in thyrocytes, the results summarized in Table 1 are different to the ones described *in vivo* (39). The discrepancy can depend on the short exposure time considered for *in vivo* experiments not reflecting continuous and rapid renewal of the intestinal epithelium. These data are just suggestive of the possible mechanisms responsible for establishment of the leaky gut phenotype upon BPA foetal exposure. They need to be specifically investigated *in vivo*.


Figure 1 Schematic drawing of the multiple bisphenol A (BPA)-induced effects contributing to the diabesity development. BPA involvement in diabesity is exerted through different mechanisms: (i) induction of systemic inflammation; (ii) organ-specific inflammation; (iii) impairment of cell–cell interaction; and (iv) dysfunction of oxidative stress control pathways. When these alterations occur in the endoderm-derived organs such as pancreas, gut, thyroid and liver, it results in diabesity. The lung involvement in the disease development is not clearly stated, but the local inflammatory cytokines production associated to BPA exposure could have a role in the diabesity progress.

Lung

The BPA is reported as a risk factor for childhood respiratory problems (asthma) and chronic obstructive pulmonary disease (COPD) (97), both exhibiting an increase of pro-inflammatory cytokines potentially associated to T2D risk. Furthermore, COPD, as well as diabesity, is associated to oxidant/antioxidant imbalance and systemic inflammation (98). BPA might have a role in the etiopathogenesis of COPD through a mechanism involving Nrf-2, a characterized target in nonendodermal cells (99,100). This result was confirmed by *in vitro* toxicogenomics analyses in immortalized thyrocytes exposed to 1 nM of BPA for 3 d, in which the activation of Nrf2-mediated oxidative stress response pathway (p-value $= 0.024$, z-score $= 1.4$) was observed (90).

Evidence of BPA toxicity in lungs came from epidemiological studies that, although not describing identical results, underline a positive correlation between maternal urinary BPA concentrations and odds of the child's wheeze (41,42).

The possible mechanisms through which prenatal exposure to BPA affected the health of the lungs have been investigated in rhesus macaques, in which BPA (GD100–GD150) altered the development of airway cells. Higher expression of *Muc5B* and *Ccsp*, genes codifying two secretory proteins, was retrieved contributing to the excessive secretion and storage of mucus. Notably, BPA exposure was conducted in order to obtain BPA levels in serum (from 2.2 to 3.3 ng mL^{-1}) within the range measured in humans (101). BPA exposure during the prenatal and postnatal phases in mice led to a predisposition to allergic asthma as well (102). BPA exposure (10 μg mL^{-1} in drinking water, from GD0 to weaning) resulted in bronchial hyper-responsiveness to allergens and eosinophilic airway inflammation in PND17 offspring (103). The asthma BPA-related phenotype was sex dependent, with women more prone to its development (104). No effect was detected after postnatal exposure to BPA by breast milk (105). Effects of BPA developmental exposure on the expression of key molecular markers of lung maturation, such as aquaporin 5, were studied in mice exposed via mother's diet (E7.5–E18.5). It was altered, and the involvement of glucocorticoid signalling was suggested (106).

Overall, the effects of developmental exposure to BPA on the lung have been analysed only recently and poorly at molecular level, a point that should be specifically addressed.

Prostate

Here, we will briefly discuss the molecular aspects of BPA effects on the prostate epithelium as not directly involved in diabesity, although diabesity markedly increases the risk of benign prostatic hyperplasia (107,108).

The BPA developmental exposure (20 μg kg^{-1} d^{-1}, GD13–GD16) in mice induced 17 beta-oestradiol levels impairing the expression of *Cyp19a1* and *Cyp11a1* during gland development. The increase of P450 aromatase (Cyp19a1) has been also associated with obesity and diabetes (108). *In utero* exposure to BPA deregulates the expression of different genes involved in prostate hyperplasia such as *Nr5a1*, *androgen receptor* and *prostatic acid phosphatase* expression (109,110). The role of BPA in prostate hyperplasia has been evidenced also in the previously mentioned *in vitro* toxicogenomic study, in which the biofunction 'hyperplasia of prostate gland' (p-value $= 0.00858$) was evidenced at 3 d of exposure (90).

The reports on the effects of *in utero* BPA exposure mainly focus on the alteration of the prostatic epithelium (43) and are related to the susceptibility of the prostate gland to adult-onset carcinogenesis following hormonal exposures. Its molecular aspects have been analysed even at epigenetic levels but will not be discussed here as far beyond the scope of this review (45,111).

Conclusion and needs

This review represents the first attempt to parallel the phenotypic and molecular effects of BPA in organs having the same developmental origin (i.e. liver, pancreas and thyroid), whose activities are strictly interplayed in diabesity. Although the molecular data are fragmentary, the available ones illustrate an important role for transcriptional regulators and epigenetic changes induced by BPA in the development of diabesity (20). This suggests that epigenetic changes, inheritable through the germ line even in the absence of continued exposure, should be considered for a proper evaluation of BPA risks. Notably, a systematic analysis of the effects on the histones code is actually missing, and a better evaluation of transgenerational effects related to endoderm-derived organs should be conducted (112). In addition, more molecular data are needed to have an *in vivo* phenotype anchoring for the endoderm-derived organs.

We suggest the gene expression profiling analysis as a valid instrument to clarify the molecular pathways involved in BPA activity in endoderm-derived organs in a first-line approach. Although the use of toxicogenomics is strongly increased in the assessment of xenobiotic activity, we found few papers applying it in molecular dissection of BPA modes of action in the endoderm-derived organs. We strongly suggest this approach because the effects of the low-dose BPA exposure can hardly be detected at phenotypic level as depending on the experimental conditions (i.e. animal model, strains and administration route). This gives rise to the strong debate on the effects of BPA at its environmental doses. Furthermore, the paucity of the molecular data negatively influences the possibility to find molecular hallmarks

of exposure or effect (i.e. genes and pathways), needed to set up correct procedures in the risk evaluation.

In our opinion, *in vitro* toxicogenomic represents a starting point, a good compromise between the costs, higher for *in vivo* toxicogenomics, and the need for pathways discovery. Indeed, we have reported here how *in vitro* toxicogenomics data from a model of endoderm-derived cells (rat follicular cells) highlight genes (i.e. codifying for junction proteins) and pathways (Nrf2 pathway, 1D-myo-inositol hexakisphosphate biosynthesis II, etc.) that play a key role in damaging endoderm organs involved in diabesity (Fig. 1). This is the evidence that the analysis of molecular data sets in organs having the same developmental origin and known to be targets of developmental exposure to BPA could lead to the identification of common/specific deregulated pathways. These pathways are hopefully usable in the risk assessment procedures as well as in the establishment of alternative methods.

Acknowledgements

Conflict of interest statement

The authors declare that they have no competing financial interests.

References

1. Vandenberg LN, Hunt PA, Myers JP, Vom Saal FS. Human exposures to bisphenol A: mismatches between data and assumptions. *Rev Environ Health* 2013; **28**: 37–58.
2. Vandenberg LN, Hauser R, Marcus M, Olea N, Welshons WV. Human exposure to bisphenol A (BPA). *Reprod Toxicol* 2007; **24**: 139–77.
3. Zalko D, Jacques C, Duplan H, Bruel S, Perdu E. Viable skin efficiently absorbs and metabolizes bisphenol A. *Chemosphere* 2011; **82**: 424–30.
4. Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Ekong J, Needham LL. Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population. *Environ Health Perspect* 2005; **113**: 391–5.
5. Fisher JW, Twaddle NC, Vanlandingham M, Doerge DR. Pharmacokinetic modeling: prediction and evaluation of route dependent dosimetry of bisphenol A in monkeys with extrapolation to humans. *Toxicol Appl Pharmacol* 2011; **257**: 122–36.
6. Calabrese EJ. U-shaped dose response in behavioral pharmacology: historical foundations. *Crit Rev Toxicol* 2008; **38**: 591–8.
7. Vandenberg LN. Non-monotonic dose responses in studies of endocrine disrupting chemicals: bisphenol A as a case study. *Dose Response* 2014; **12**: 259–76.

8. Vandenberg LN, Colborn T, Hayes TB *et al*. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. *Endocr Rev* 2012; **33**: 378–455.
9. Bertoli S, Leone A, Battezzati A. Human bisphenol A exposure and the "diabesity phenotype". *Dose Response* 2015; **13** 1559325815599173.
10. Kuiper GG, Lemmen JG, Carlsson B *et al*. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. *Endocrinology* 1998; **139**: 4252–63.
11. Fang H, Tong W, Perkins R, Soto AM, Prechtl NV, Sheehan DM. Quantitative comparisons of *in vitro* assays for estrogenic activities. *Environ Health Perspect* 2000; **108**: 723–9.
12. Alonso-Magdalena P, Ropero AB, Carrera MP *et al*. Pancreatic insulin content regulation by the estrogen receptor ER alpha. *PLoS One* 2008; **3** e2069.
13. Soriano S, Alonso-Magdalena P, García-Arévalo M *et al*. Rapid insulinotropic action of low doses of bisphenol-A on mouse and human islets of Langerhans: role of estrogen receptor β. *PLoS One* 2012; **7** e31109.
14. Nadal A, Ropero AB, Laribi O, Maillet M, Fuentes E, Soria B. Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen receptor alpha and estrogen receptor beta. *Proc Natl Acad Sci U S A* 2000; **97**: 11603–8.
15. Thomas PDJ. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. *J Steroid Biochem Mol Biol* 2006; **102**: 175–9.
16. Ge LC, Chen ZJ, Liu HY *et al*. Involvement of activating ERK1/2 through G protein coupled receptor 30 and estrogen receptor α/β in low doses of bisphenol A promoting growth of Sertoli TM4 cells. *Toxicol Lett* 2014; **226**: 81–9.
17. Sheng Z-G, Tang Y, Liu Y-X *et al*. Low concentrations of bisphenol A suppress thyroid hormone receptor transcription through a nongenomic mechanism. *Toxicol Appl Pharmacol* 2012; **259**: 133–42.
18. Song H, Zhang T, Yang P *et al*. Low doses of bisphenol A stimulate the proliferation of breast cancer cells via ERK1/2/ERRγ signals. *Toxicol Vitr* 2015; **30**: 521–8.
19. Teng C, Goodwin B, Shockley K *et al*. Bisphenol A affects androgen receptor function via multiple mechanisms. *Chem Biol Interact* 2013; **203**: 556–64.
20. Rezg R, El-Fazaa S, Gharbi N, Mornagui B. Bisphenol A and human chronic diseases: current evidences, possible mechanisms, and future perspectives. *Environ Int* 2014; **64**: 83–90.
21. Gentilcore D, Porreca I, Rizzo F *et al*. Bisphenol A interferes with thyroid specific gene expression. *Toxicology* 2013; **304C**: 21–31.
22. Valentino R, D'Esposito V, Passaretti F *et al*. Bisphenol-A impairs insulin action and up-regulates inflammatory pathways in human subcutaneous adipocytes and 3T3-L1 cells. *PLoS One* 2013; **8** e82099.
23. Susiarjo M, Sasson I, Mesaros C, Bartolomei MS. Bisphenol a exposure disrupts genomic imprinting in the mouse. *PLoS Genet* 2013; **9**: e1003401.
24. Inoue H, Tsuruta A, Kudo S *et al*. Bisphenol a glucuronidation and excretion in liver of pregnant and nonpregnant female rats. *Drug Metab Dispos* 2005; **33**: 55–9.
25. Mahalingaiah S, Meeker JD, Pearson KR *et al*. Temporal variability and predictors of urinary bisphenol A concentrations in men and women. *Environ Health Perspect* 2008; **116**: 173–8.
26. Nagel SC, vom Saal FS, Thayer KA, Dhar MG, Boechler M, Welshons WV. Relative binding affinity-serum modified access (RBA-SMA) assay predicts the relative in vivo bioactivity of the xenoestrogens bisphenol A and octylphenol. *Environ Health Perspect* 1997; **105**: 70–6.

27. Nagel SC, vom Saal FS, Welshons WV. Developmental effects of estrogenic chemicals are predicted by an in vitro assay incorporating modification of cell uptake by serum. *J Steroid Biochem Mol Biol* 1999; **69**: 343–57.

28. Gioiosa L, Palanza P, Parmigiani S, Vom Saal FS. Risk evaluation of endocrine-disrupting chemicals: effects of developmental exposure to low doses of bisphenol A on behavior and physiology in mice (*Mus musculus*). *Dose Response* 13:1559325815610760.

29. Golub MS, Wu KL, Kaufman FL *et al*. Bisphenol A: developmental toxicity from early prenatal exposure. *Birth Defects Res B Dev Reprod Toxicol* 2010; **89**: 441–66.

30. Kundakovic M, Champagne FA. Epigenetic perspective on the developmental effects of bisphenol A. *Brain Behav Immun* 2011; **25**: 1084–93.

31. Meeker JD. Exposure to environmental endocrine disruptors and child development. *Arch Pediatr Adolesc Med* 2012; **166**: 952–8.

32. Rochester JR. Bisphenol A and human health: a review of the literature. *Reprod Toxicol* 2013;**42**:132–55.

33. Xin F, Susiarjo M, Bartolomei MS. Multigenerational and transgenerational effects of endocrine disrupting chemicals: a role for altered epigenetic regulation? *Semin Cell Dev Biol* 2015; **43**: 66–75.

34. Tyl RW, Myers CB, Marr MC *et al*. Two-generative reproductive toxicity study of dietary bisphenol A in CD-1 (Swiss) mice. *Toxicol Sci* 2008; **104**: 362–84.

35. Tyl RW, Myers CB, Marr MC *et al*. Three-generation reproductive toxicity study of dietary bisphenol A in CD Sprague-Dawley rats. *Toxicol Sci* 2002; **68**: 121–46.

36. Alonso-Magdalena P, Vieira E, Soriano S *et al*. Bisphenol A exposure during pregnancy disrupts glucose homeostasis in mothers and adult male offspring. *Environ Health Perspect* 2010; **118**: 1243–50.

37. Bodin J, Bølling AK, Becher R, Kuper F, Løvik M, Nygaard UC. Transmaternal bisphenol A exposure accelerates diabetes type 1 development in NOD mice. *Toxicol Sci* 2014; **137**: 311–23.

38. Zoeller RT, Bansal R, Parris C. Bisphenol-A, an environmental contaminant that acts as a thyroid hormone receptor antagonist *in vitro*, increases serum thyroxine, and alters RC3/neurogranin expression in the developing rat brain. *Endocrinology* 2005; **146**: 607–12.

39. Braniste V, Jouault A, Gaultier E *et al*. Impact of oral bisphenol A at reference doses on intestinal barrier function and sex differences after perinatal exposure in rats. *Proc Natl Acad Sci U S A* 2010; **107**: 448–53.

40. Otsuka H, Sugimoto M, Ikeda S, Kume S. Effects of bisphenol A administration to pregnant mice on serum Ca and intestinal Ca absorption. *Anim Sci J* 2012; **83**: 232–7.

41. Spanier AJ, Kahn RS, Kunselman AR *et al*. Prenatal exposure to bisphenol A and child wheeze from birth to 3 years of age. *Environ Health Perspect* 2012; **120**: 916–20.

42. Donohue KM, Miller RL, Perzanowski MS *et al*. Prenatal and postnatal bisphenol A exposure and asthma development among inner-city children. *J Allergy Clin Immunol* 2013; **131**: 736–42.

43. Ogura Y, Ishii K, Kanda H *et al*. Bisphenol A induces permanent squamous change in mouse prostatic epithelium. *Differentiation* 2007; **75**: 745–56.

44. Sun H, Shen O-X, Wang X-R, Zhou L, Zhen S-Q, Chen X-D. Anti-thyroid hormone activity of bisphenol A, tetrabromobisphenol A and tetrachlorobisphenol A in an improved reporter gene assay. *Toxicol In Vitro* 2009; **23**: 950–4.

45. Ho S-M, Tang W-Y, Belmonte de Frausto J, Prins GS. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. *Cancer Res* 2006; **66**: 5624–32.

46. Rönn M, Kullberg J, Karlsson H *et al*. Bisphenol A exposure increases liver fat in juvenile fructose-fed Fischer 344 rats. *Toxicol* 2013; **303**: 125–32.

47. Marmugi A, Ducheix S, Lasserre F *et al*. Low doses of bisphenol A induce gene expression related to lipid synthesis and trigger triglyceride accumulation in adult mouse liver. *Hepatology* 2012; **55**: 395–407.

48. Poupon R. Differentiating between benign and non-benign obesity: look at the liver. *Gastroentérologie Clin Biol* 2010; **34**: 244–5.

49. Kirchner H, Sinha I, Gao H *et al*. Altered DNA methylation of glycolytic and lipogenic genes in liver from obese and type 2 diabetic patients. *Mol Metab* 2016; **5**: 171–83.

50. Zhang J, Cooke GM, Curran IHA, Goodyer CG, Cao X-L. GC-MS analysis of bisphenol A in human placental and fetal liver samples. *J Chromatogr B Analyt Technol Biomed Life Sci* 2011; **879**: 209–14.

51. Nahar MS, Liao C, Kannan K, Dolinoy DC. Fetal liver bisphenol A concentrations and biotransformation gene expression reveal variable exposure and altered capacity for metabolism in humans. *J Biochem Mol Toxicol* 2013; **27**: 116–23.

52. Nishizawa H, Imanishi S, Manabe N. Effects of exposure *in utero* to bisphenol A on the expression of aryl hydrocarbon receptor, related factors, and xenobiotic metabolizing enzymes in murine embryos. *J Reprod Dev* 2005; **51**: 593–605.

53. Nahar MS, Kim JH, Sartor MA, Dolinoy DC. Bisphenol A-associated alterations in the expression and epigenetic regulation of genes encoding xenobiotic metabolizing enzymes in human fetal liver. *Environ Mol Mutagen* 2014; **55**: 184–95.

54. Xia W, Jiang Y, Li Y *et al*. Early-life exposure to bisphenol A induces liver injury in rats involvement of mitochondria-mediated apoptosis. *PLoS One* 2014; **9** e90443.

55. Ma Y, Xia W, Wang DQ *et al*. Hepatic DNA methylation modifications in early development of rats resulting from perinatal BPA exposure contribute to insulin resistance in adulthood. *Diabetologia* 2013; **56**: 2059–67.

56. Kim JH, Sartor MA, Rozek LS *et al*. Perinatal bisphenol A exposure promotes dose-dependent alterations of the mouse methylome. *BMC Genomics* 2014; **15**: 30.

57. van Esterik JCJ, Vitins AP, Hodemaekers HM *et al*. Liver DNA methylation analysis in adult female C57BL/6JxFVB mice following perinatal exposure to bisphenol A. *Toxicol Lett* 2014; **232**: 293–300.

58. Strakovsky RS, Wang H, Engeseth NJ *et al*. Developmental bisphenol A (BPA) exposure leads to sex-specific modification of hepatic gene expression and epigenome at birth that may exacerbate high-fat diet-induced hepatic steatosis. *Toxicol Appl Pharmacol* 2015; **284**: 101–12.

59. Murray M. Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. *Curr Drug Metab* 2006; 67–81.

60. Connor T, Martin SD, Howlett KF, McGee SL. Metabolic remodelling in obesity and type 2 diabetes: pathological or protective mechanisms in response to nutrient excess? *Clin Exp Pharmacol Physiol* 2015; **42**: 109–15.

61. Cabaton NJ, Canlet C, Wadia PR *et al*. Effects of low doses of bisphenol A on the metabolome of perinatally exposed CD-1 mice. *Environ Health Perspect* 2013; **121**: 586–93.

62. Jiang Y, Xia W, Zhu Y *et al*. Mitochondrial dysfunction in early life resulted from perinatal bisphenol A exposure contributes to hepatic steatosis in rat offspring. *Toxicol Lett* 2014; **228**: 85–92.

63. Cooper ME, El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. *Circ Res* 2010; **107**: 1403–13.

64. Raza H, John A, Howarth FC. Increased oxidative stress and mitochondrial dysfunction in Zucker diabetic rat liver and brain. *Cell Physiol Biochem* 2015; **35**: 1241–51.

65. Shankar A, Teppala S. Relationship between urinary bisphenol A levels and diabetes mellitus. *J Clin Endocrinol Metab* 2011; **96**: 3822–6.

66. Wang T, Li M, Chen B *et al*. Urinary bisphenol A (BPA) concentration associates with obesity and insulin resistance. *J Clin Endocrinol Metab* 2012; **97**: E223–7.

67. Kluth O, Matzke D, Kamitz A *et al*. Identification of four mouse diabetes candidate genes altering β-cell proliferation. *PLoS Genet* 2015; **11** e1005506.

68. García-Arevalo M, Alonso-Magdalena P, Rebelo Dos Santos J, Quesada I, Carneiro EM, Nadal A. Exposure to bisphenol-A during pregnancy partially mimics the effects of a high-fat diet altering glucose homeostasis and gene expression in adult male mice. *PLoS One* 2014; **9** e100214.

69. Angle BM, Do RP, Ponzi D *et al*. Metabolic disruption in male mice due to fetal exposure to low but not high doses of bisphenol A (BPA): evidence for effects on body weight, food intake, adipocytes, leptin, adiponectin, insulin and glucose regulation. *Reprod Toxicol* 2013; **42**: 256–68.

70. Yang Y, Kim S, Hong Y, Ahn J, Park M. Environmentally relevant levels of bisphenol A may accelerate the development of type II diabetes mellitus in adolescent Otsuka Long Evans Tokushima fatty rats. *Toxicol Environ Health Sci* 2014; **6**: 41–7.

71. Wei J, Lin Y, Li Y *et al*. Perinatal exposure to bisphenol A at reference dose predisposes offspring to metabolic syndrome in adult rats on a high-fat diet. *Endocrinology* 2011; **152**: 3049–61.

72. Whitehead R, Guan H, Arany E, Cernea M, Yang K. Prenatal exposure to bisphenol A alters mouse fetal pancreatic morphology and islet composition. *Horm Mol Biol Clin Investig* 2016; **25**: 171–9.

73. Liu J, Yu P, Qian W *et al*. Perinatal bisphenol A exposure and adult glucose homeostasis: identifying critical windows of exposure. *PLoS One* 2013; **8** e64143.

74. Alonso-Magdalena P, Morimoto S, Ripoll C, Fuentes E, Nadal A. The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function *in vivo* and induces insulin resistance. *Environ Health Perspect* 2006; **114**: 106–12.

75. Lin Y, Sun X, Qiu L *et al*. Exposure to bisphenol A induces dysfunction of insulin secretion and apoptosis through the damage of mitochondria in rat insulinoma (INS-1) cells. *Cell Death Dis* 2013; **4** e460.

76. Song L, Xia W, Zhou Z *et al*. Low-level phenolic estrogen pollutants impair islet morphology and β-cell function in isolated rat islets. *J Endocrinol* 2012; **215**: 303–11.

77. Carchia E, Porreca I, Almeida PJ *et al*. Evaluation of low doses BPA-induced perturbation of glycemia by toxicogenomics points to a primary role of pancreatic islets and to the mechanism of toxicity. *Cell Death Dis* 2015; **6** e1959.

78. Hannon TS, Arslanian SA. The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. *Ann N Y Acad Sci* 2015; **1353**: 113–37.

79. Duntas LH, Orgiazzi J, Brabant G. The interface between thyroid and diabetes mellitus. *Clin Endocrinol (Oxf)* 2011; **75**: 1–9.

80. Molehin D, Dekker Nitert M, Richard K. Prenatal exposures to multiple thyroid hormone disruptors: effects on glucose and lipid metabolism. *J Thyroid Res* 2016; **2016** 8765049.

81. Terrien X, Fini J-B, Demeneix BA, Schramm K-W, Prunet P. Generation of fluorescent zebrafish to study endocrine disruption and potential crosstalk between thyroid hormone and corticosteroids. *Aquat Toxicol* 2011; **105**: 13–20.

82. Meeker JD, Ferguson KK. Relationship between urinary phthalate and bisphenol A concentrations and serum thyroid measures in U.S. adults and adolescents from the National Health and Nutrition Examination Survey (NHANES) 2007–2008. *Environ Health Perspect* 2011; **119**: 1396–402.

83. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. *JAMA* 2015; **314**: 1021–9.

84. Tóth PP, Potter DME. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003–2006. *J Clin Lipidol* 2012; **6**: 325–30.

85. Chevrier J, Gunier RB, Bradman A *et al*. Maternal urinary bisphenol A during pregnancy and maternal and neonatal thyroid function in the CHAMACOS study. *Environ Health Perspect* 2013; **121**: 138–44.

86. Kobayashi K, Miyagawa M, Wang R-S, Suda M, Sekiguchi S, Honma T. Effects of *in utero* and lactational exposure to bisphenol A on thyroid status in F1 rat offspring. *Ind Health* 2005; **43**: 685–90.

87. Xu X, Liu Y, Sadamatsu M *et al*. Perinatal bisphenol A affects the behavior and SRC-1 expression of male pups but does not influence on the thyroid hormone receptors and its responsive gene. *Neurosci Res* 2007; **58**: 149–55.

88. Viguié C, Collet SH, Gayrard V *et al*. Maternal and fetal exposure to bisphenol A is associated with alterations of thyroid function in pregnant ewes and their newborn lambs. *Endocrinology* 2013; **154**: 521–8.

89. Moriyama K, Tagami T, Akamizu T *et al*. Thyroid hormone action is disrupted by bisphenol A as an antagonist. *J Clin Endocrinol Metab* 2002; **87**: 5185–90.

90. Porreca I, Ulloa Severino L, D'Angelo F *et al*. "Stockpile" of slight transcriptomic changes determines the indirect genotoxicity of low-dose BPA in thyroid cells. *PLoS One* 2016; **11** e0151618.

91. Chakraborty A, Koldobskiy MA, Bello NT *et al*. Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. *Cell* 2010; **143**: 897–910.

92. de Kort S, Keszthelyi D, Masclee AAM. Leaky gut and diabetes mellitus: what is the link? *Obes Rev* 2011; **12**: 449–58.

93. Teixeira TFS, Collado MC, Ferreira CLLF, Bressan J, Peluzio M do CG. Potential mechanisms for the emerging link between obesity and increased intestinal permeability. *Nutr Res* 2012;**32**:637–47.

94. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. *J Allergy Clin Immunol* 2009;**124**:3–20; quiz 21–2.

95. Homma H, Hoy E, Xu D-Z, Lu Q, Feinman R, Deitch EA. The female intestine is more resistant than the male intestine to gut injury and inflammation when subjected to conditions associated with shock states. *Am J Physiol Gastrointest Liver Physiol* 2005; **288**: G466–72.

96. Xiao X, Mruk DD, Tang EI *et al*. Environmental toxicants perturb human Sertoli cell adhesive function via changes in F-actin organization mediated by actin regulatory proteins. *Hum Reprod* 2014; **29**: 1279–91.

97. Drummond MB. Obstructive airway disease in urban populations. *Curr Opin Pulm Med* 2014; **20**: 180–5.

98. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2016; **138**: 16–27.

99. Kim J, Cha Y-N, Surh Y-J. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. *Mutat Res* 2010; **690**: 12–23.

100. Chepelev NL, Enikanolaiye MI, Chepelev LL *et al*. Bisphenol A activates the Nrf1/2-antioxidant response element pathway in HEK 293 cells. *Chem Res Toxicol* 2013; **26**: 498–506.

101. Van Winkle LS, Murphy SR, Boetticher MV, VandeVoort CA. Fetal exposure of rhesus macaques to bisphenol A alters cellular development of the conducting airway by changing epithelial secretory product expression. *Environ Health Perspect* 2013; **121**: 912–8.

102. O'Brien E, Bergin IL, Dolinoy DC *et al*. Perinatal bisphenol A exposure beginning before gestation enhances allergen sensitization, but not pulmonary inflammation, in adult mice. *J Dev Orig Health Dis* 2014; **5**: 121–31.

103. Midoro-Horiuti T, Tiwari R, Watson CS, Goldblum RM. Maternal bisphenol A exposure promotes the development of experimental asthma in mouse pups. *Environ Health Perspect* 2010; **118**: 273–7.

104. Bauer SM, Roy A, Emo J, Chapman TJ, Georas SN, Lawrence BP. The effects of maternal exposure to bisphenol A on allergic lung inflammation into adulthood. *Toxicol Sci* 2012; **130**: 82–93.

105. Nakajima Y, Goldblum RM, Midoro-Horiuti T. Fetal exposure to bisphenol A as a risk factor for the development of childhood asthma: an animal model study. *Environ Health* 2012; **11**: 8.

106. Hijazi A, Guan H, Cernea M, Yang K. Prenatal exposure to bisphenol A disrupts mouse fetal lung development. *FASEB J* 2015; **29**: 4968–77.

107. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. *J Urol* 2013; **189**: S102–6.

108. Williams GP. The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. *Eur J Cancer Prev* 2010; **19**: 256–71.

109. Ramos JG, Varayoud J, Kass L *et al*. Bisphenol A induces both transient and permanent histofunctional alterations of the hypothalamic-pituitary-gonadal axis in prenatally exposed male rats. *Endocrinology* 2003; **144**: 3206–15.

110. Ramos JG, Varayoud J, Sonnenschein C, Soto AM, Muñoz De Toro M, Luque EH. Prenatal exposure to low doses of bisphenol A alters the periductal stroma and glandular cell function in the rat ventral prostate. *Biol Reprod* 2001; **65**: 1271–7.

111. Yean Wong RL, Wang Q, Treviño LS *et al*. Identification of secretaglobin Scgb2a1 as a target for developmental reprogramming by BPA in the rat prostate. *Epigenetics* 2015; **10**: 127–34.

112. Manikkam M, Tracey R, Guerrero-Bosagna C, Skinner MK. Plastics derived endocrine disruptors (BPA, DEHP and DBP) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. *PLoS One* 2013; **8** e55387.

113. Belkin AM, Burridge K. Localization of utrophin and aciculin at sites of cell-matrix and cell-cell adhesion in cultured cells. *Exp Cell Res* 1995; **221**: 132–40.

114. Dumbauld DW, García AJ. A helping hand: how vinculin contributes to cell-matrix and cell-cell force transfer. *Cell Adh Migr* 2014; **8**: 550–7.

115. Yi C, Troutman S, Fera D *et al*. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. *Cancer Cell* 2011; **19**: 527–40.

116. Grego-Bessa J, Hildebrand J, Anderson KV. Morphogenesis of the mouse neural plate depends on distinct roles of cofilin 1 in apical and basal epithelial domains. *Development* 2015; **142**: 1305–14.

117. Yang G, Li Q, Ren S *et al*. Proteomic, functional and motif-based analysis of C-terminal Src kinase-interacting proteins. *Proteomics* 2009; **9**: 4944–61.

118. Yamanaka T, Ohno S. Role of Lgl/Dlg/Scribble in the regulation of epithelial junction, polarity and growth. *Front Biosci* 2008; **13**: 6693–707.

119. Adachi M, Inoko A, Hata M *et al*. Normal establishment of epithelial tight junctions in mice and cultured cells lacking expression of ZO-3, a tight-junction MAGUK protein. *Mol Cell Biol* 2006; **26**: 9003–15.

120. Brady-Kalnay SM, Flint AJ, Tonks NK. Homophilic binding of PTP mu, a receptor-type protein tyrosine phosphatase, can mediate cell-cell aggregation. *J Cell Biol* 1993; **122**: 961–72.

121. Gujral TS, Karp ES, Chan M, Chang BH, MacBeath G. Family-wide investigation of PDZ domain-mediated protein-protein interactions implicates β-catenin in maintaining the integrity of tight junctions. *Chem Biol* 2013; **20**: 816–27.

122. Hirate Y, Sasaki H. The role of angiomotin phosphorylation in the Hippo pathway during preimplantation mouse development. *Tissue Barriers* 2014; **2** e28127.

123. Wang Z, Sandiford S, Wu C, Li SS-C. Numb regulates cell-cell adhesion and polarity in response to tyrosine kinase signalling. *EMBO J* 2009; **28**: 2360–73.

124. Benais-Pont G, Punn A, Flores-Maldonado C *et al*. Identification of a tight junction-associated guanine nucleotide exchange factor that activates Rho and regulates paracellular permeability. *J Cell Biol* 2003; **160**: 729–40.